Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Sentiment To Be Tested

Published 11/12/2020, 06:06 AM
Updated 07/09/2023, 06:31 AM

Has the market finally started to turn its attention back towards the virus after the US election, and news from Pfizer (NYSE:PFE) hogged the newsreels? In the US, the number of hospitalized COVID patients reached 65,368 yesterday, surpassing Tuesday's record for the most hospitalizations since April, according to the COVID Tracking Project. Yesterday New York issued new restrictions for most bars and restaurants as well as limiting the number of people of private residence gatherings.

I think it is hard to say that with any certainty, but It could be a factor in this morning's London session weakness in equities, although it is worth considering that the DAX has risen 14% in the last 10 sessions, so perhaps some profit-taking is overdue. 

Still, it's questionable whether this will matter next week, considering the vaccine's tailwinds are likely to continue to dominate financial markets. But for today, as the market debates whether hedge funds have had enough of the rotation theme. Investors are reacting fairly negatively to the latest COVID headline uglies.

But at least for today so far the nexus of stalling stock markets and COVID headline uglies typically make for bad bedfellows.

The other thing to note is investors aren't exactly piling back into fixed income in any great size at the moment.

Oil 

OPEC officials have suggested that oil current production cuts may be extended 3-6 months when the group meets at the end of November in response to recent macro developments. The OPEC+ cuts are still driving global inventory draws but a demand stalled environment caused by a surge in coronavirus infections in the US and Europe means it is prudent for an even more gradual easing in 2021. And possibly a willingness to offer up deeper cuts  as we head into an unvaccinated winter of COVID gloom  

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Hard To Consider EUR/USD Longs Before 1.1675

There was good USD buying across G10 yesterday; it felt like a continuation of USD short covering. Stocks and risk sentiment, in general, feels a bit tired after the boost earlier in the week on positive covid vaccine news. EUR/USD has been one of the preferred instruments to express bearish USD view since the US election, so that might be where there is the most wood to chop no, it's challenging to consider re-engaging longs before 1.1675-1.1700

Latest comments

hello
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.